NASDAQ:CMMB Chemomab Therapeutics Q2 2025 Earnings Report $1.74 -0.09 (-4.92%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$1.74 0.00 (0.00%) As of 07/10/2026 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Chemomab Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.80Beat/MissBeat by +$0.44One Year Ago EPSN/AChemomab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AChemomab Therapeutics Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time6:00PM ETUpcoming EarningsChemomab Therapeutics' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K) Chemomab Therapeutics Earnings HeadlinesChemomab Therapeutics to Merge With Scipher in All-Stock Deal, Pivot to RA Drug TrialJuly 10 at 2:02 AM | americanbankingnews.comChemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks TranscriptJuly 8 at 1:00 PM | seekingalpha.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.July 11 at 1:00 AM | Altimetry (Ad)Chemomab to merge with Scipher MedicineJuly 8 at 12:31 PM | msn.comChemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid ArthritisJuly 8 at 7:35 AM | globenewswire.comChemomab Therapeutics Stock Short Interest Report | NASDAQ:CMMB | BenzingaJuly 7, 2026 | benzinga.comSee More Chemomab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email. Email Address About Chemomab TherapeuticsChemomab Therapeutics (NASDAQ:CMMB) (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development. Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes. Its lead oncology programs employ novel bispecific formats intended to engage immune effector cells against solid tumors, while infectious disease programs focus on broad-spectrum neutralization of viral pathogens. Chemomab’s inflammatory disease efforts seek to modulate autoimmune pathways through highly selective receptor blockade. Headquartered in Shanghai with a presence in the United States, Chemomab fosters global collaboration with academic institutions and contract research organizations. The company was founded by a team of immunology and protein engineering experts and is led by a management group with extensive experience in biotechnology R&D and regulatory affairs. Through strategic partnerships and disciplined clinical development, Chemomab Therapeutics is positioning itself to address significant unmet medical needs in multiple therapeutic areas.View Chemomab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Why WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real ProfitLockheed Martin Secures the Ultimate Defense Moat Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
